Amid the exponential rise in COVID-19 cases in China, the pharmaceutical industries are finding it difficult to cope with the high demand for medicines after the Xi Jinping-led government announced relaxations in its zero-Covid policy.
2022 was a momentous year for China, backstopped by an end-of-year scrabble to survive the pandemic of COVID-19 from December onwards. What the sequence of events taught the world is that the Chinese Communist Party (CCP) may be incredibly good at controlling its population, but it is not so
But it appears that his authoritarian rule is being questioned as the recent angry protests by the people across China over Xi's Zero-Covid policy is a crucial development.
China had its most difficult year under Xi's rule as it reeled from his costly zero-Covid policy - from months of overzealous enforcement that crushed the economy and stoked historic public discontent, to a wholesale abandonment so abrupt that left a fragile health system scrambling to cope
Turkish government which initially accepted Chinese vaccines is now scrutinising its efficacy after learning of China's involvement in data tempering of side effects only to enhance its vaccine sale.
This was well below forecast and seems to have been caused by lockdowns associated with its Zero Covid policy, the London-based consultancy said in a report.
Amid a surge in COVID-19 cases in the country, China on Monday announced to stop the coronavirus quarantine rule for inbound travellers from January 8.
After China abandoned its restrictive "zero Covid" policy about two weeks ago, regional numbers of infected persons with coronavirus point to explosive outbreaks and overstretched healthcare systems, writes Chang Che, Asia technology correspondent for The New York Times (NYT).
The Chinese economy was already struggling when Beijing abruptly relaxed its stringent zero-Covid policy. Retail sales had contracted in November because of widespread lockdowns, and unemployment had surged to the highest level in six months.
Just four days earlier, the Chinese government reported its first COVID-related deaths -just two of them, mind you - since Beijing released a ten-point easing plan on 7 December. This signaled a turnaround from the nation's controversial and harsh zero-COVID policy.